P073 Enhancing the MFSD2A protein for the treatment of colitis-associated cancer: novel insights for pathogenesis and treatment

S Cagliani,L Massimino,A Facoetti,S Spanò,C Errico,T L Parigi,G Colasante,S Danese,F Ungaro

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0203

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background The intrinsic connection between inflammation and tumor promotion is well characterized and is a key pathogenic event in patients with colorectal cancer (CRC). A small fraction of patients with CRC suffers from genetic predisposition. However chronic inflammation, such as ulcerative colitis (UC), increases the risk of intestinal carcinogenesis, thus strengthening the connection between these conditions. A few years ago, our laboratory described that the intestinal endothelium isolated from actively inflamed UC patients displayed defective production of inflammation-resolving DHA-derived metabolites, by comparison with healthy controls and tissues in remission. We also reported that the Major Facilitator Superfamily Domain containing 2A (MFSD2A) participated in the production of the inflammation-resolving DHA-derived metabolites by the intestinal endothelium of patients with UC in remission, ameliorating colonic inflammation. Therefore, we hypothesized that the endothelial MFSD2A also has a role in preventing and/or counteracting cancer-associated inflammation. Methods Human Intestinal Microvascular Endothelial Cells (HIMEC) isolated from CRC and healthy samples were transduced with either MFSD2A protein-encoding lentiviral vectors (MFSD2A) or GFP as control, or MFSD2A targeting shRNA or its scramble, and were analyzed by lipidomics. Furthermore, Caco-2 cells co-cultured with HIMEC-MFSD2A were analyzed by FACS, evaluating their proliferation. Moreover, an orthotopic model of CRC was made intrarectally injecting CD1 nude mice with a cell mixture of Caco-2 and HUVEC overexpressing MFSD2A or GFP as control. Mice were gavaged with DHA-ethyl-ester or PBS. FACS analysis was performed on tumor and colonic samples. Results Lipidomic analysis revealed that the loss of MFSD2A in CRC is detrimental because there is a reduced production of pro-resolving lipids confirming that, as for UC, MFSD2A is important for the maintenance of an adequate balance between pro-resolving and pro-inflammatory phenotype. Moreover, enhancing MFSD2A expression at endothelial level limits Caco-2 cell proliferation, supporting its beneficial role. In addition, DHA administration in mice ameliorated clinical symptoms of inflammation upon intestinal endothelial MFSD2A overexpression, supporting the beneficial role of MFSD2A in vivo. Conclusion Tumor-associated inflammation remains a crucial hallmark of CRC. Our study seeks to identify the role of MFSD2A in the resolution phase of inflammation, pointing out alternative therapies for CRC treatment. These data suggested that MFSD2A might contrast the tumor-associated inflammation and ensure the correct balance between pro-inflammatory and pro-resolving milieu.

gastroenterology & hepatology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the intrinsic connection between inflammation and tumor promotion, especially in patients with colorectal cancer (CRC), and this connection is a key pathogenic event. Chronic inflammation, such as ulcerative colitis (UC), increases the risk of intestinal carcinogenesis, which further strengthens the association between these conditions. The authors' previous research has shown that in the intestinal endothelial cells of patients with active UC, there is a defect in the production of inflammation - resolving metabolites derived from DHA (docosahexaenoic acid), and MFSD2A (major facilitator superfamily domain - containing protein 2A) is involved in the production of inflammation - resolving DHA - derived metabolites in the intestinal endothelial cells of patients with UC in remission, which helps to improve colonic inflammation. Based on this, the authors hypothesized that endothelial MFSD2A also plays a role in preventing and/or combating cancer - related inflammation.

To test this hypothesis, the research team conducted experiments by the following methods:
- Transduce human intestinal microvascular endothelial cells (HIMEC) isolated from CRC and healthy samples with a lentiviral vector encoding the MFSD2A protein or GFP as a control, and analyze these cells by lipidomics.
- Evaluate the proliferation of Caco - 2 cells co - cultured with HIMEC overexpressing MFSD2A.
- Establish an orthotopic rectal CRC model, inject a mixture of Caco - 2 and HUVEC cells overexpressing MFSD2A or GFP as a control into CD1 nude mice, and orally administer DHA ethyl ester or PBS, followed by FACS analysis of tumor and colon samples.

The research results show that the deletion of MFSD2A in CRC is harmful because it reduces the production of pro - resolving lipids, confirming the importance of MFSD2A for maintaining the appropriate balance between pro - resolving and pro - inflammatory phenotypes. In addition, enhancing the expression of MFSD2A at the endothelial level can limit the proliferation of Caco - 2 cells, supporting its beneficial effect. In mice, the administration of DHA improved the clinical symptoms of inflammation in the case of intestinal endothelial MFSD2A overexpression, further supporting the beneficial effect of MFSD2A in vivo.

In conclusion, this study aims to explore the role of MFSD2A in the inflammation - resolving phase, propose alternative therapies for CRC treatment, and the data suggest that MFSD2A may combat tumor - related inflammation and ensure the correct balance between the pro - inflammatory and pro - resolving environments.